MPM BioImpact’s Zai Lab ZLAB Stock Holding History

MPM BioImpact’s Portfolio ZLAB Stock Details ZLAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-745,060	Closed	-$25.3M	–	54
2025 Q3	$25.3M	Hold	745,060	–	–	4.13%	7
2025 Q2	$26.1M	Sell	745,060 -88,599	-11%	-$2.91M	4.51%	3
2025 Q1	$30.1M	Buy	833,659 +33,659	+4%	+$1.04M	5.18%	3
2024 Q4	$21M	Buy	+800,000	New	+$22.2M	2.97%	9

Other funds holding ZLAB

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

MPM BioImpact's ZLAB Position: Q4 2025 in Review

MPM BioImpact sold out of Zai Lab (ZLAB) in Q4 2025, closing a stake of 745,060 shares — an estimated $25.3M sold.

MPM BioImpact first reported a position in ZLAB in Q4 2024 and held it in 4 quarters. The position peaked at $30.1M in Q1 2025. 126 funds tracked by Wall St. Rank hold ZLAB as of Q4 2025.

MPM BioImpact reported no remaining Zai Lab position as of Q4 2025 after selling out during the quarter.
MPM BioImpact sold 745,060 Zai Lab shares in Q4 2025, an estimated $25.3M.
MPM BioImpact first reported a position in Zai Lab in Q4 2024 and held it in 4 quarters.
MPM BioImpact's Zai Lab position peaked at $30.1M in Q1 2025.
126 funds tracked by Wall St. Rank held Zai Lab as of Q4 2025.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.